CoDaTherapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair based on a new platform technology known as “Gap Junction Modulation.”
Founded on patented inventions and data generated in the laboratories of Professor Colin Green (University of Auckland) and Dr. David Becker (University College London), CoDa is building a portfolio of novel, proprietary compounds that, through control of gap junctions, can reduce cell to cell communication and improve wound healing and tissue repair post-injury.
These first-in-class compounds represent a new paradigm in wound care – improving wound healing while managing inflammation and scarring.
Our patent-protected lead product candidate, Nexagon™, dramatically
improves the body’s ability to repair damaged tissue and has
broad applications. The technology has been shown to work in a variety
of tissue types including, eye, skin, brain, nerve, and spinal cord.
Numerous pre-clinical models show improved wound closure and healing
rates, as well as reduced lesion spread (cell death), swelling, inflammation,
and scarring.
News & Articles
CoDaTherapeutics Secures US$10.0 Million in Additional Series A Financing
February 21 2007, 6:27 PM EST
Wound Healing Drug Development Company Will Use Funds to Achieve Clinical Development Milestones.
CoDaTherapeutics Announces
Series A Financing
Oct 10 2006, 3:44 PM EST
SAN DIEGO, Oct. 10 /PRNewswire/ -- CoDaTherapeutics, Inc., a biopharmaceutical company founded in 2005, today announced the completion of a $10 million Series A preferred stock financing by Domain Associates...